# Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers

Study · id `cardio:ct-nct07566091` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07566091](<https://clinicaltrials.gov/study/NCT07566091>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07566091

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2034 participants.

## Technical summary

Registry record NCT07566091. Randomized; double masking; primary purpose treatment. Start 2026-10-06 (actual); primary completion 2027-06-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 2034 participants (planned count; ClinicalTrials.gov record NCT07566091, source copy `cardio:ctgov-nct07566091-2026-10-07`, retrieved 2026-10-26)
- Started: 2026-10-06 (actual) (ClinicalTrials.gov record NCT07566091, source copy `cardio:ctgov-nct07566091-2026-10-07`, retrieved 2026-10-26)
- Primary completion: 2027-06-15 (anticipated) (ClinicalTrials.gov record NCT07566091, source copy `cardio:ctgov-nct07566091-2026-10-07`, retrieved 2026-10-26)
- Completion: 2028-06-15 (anticipated) (ClinicalTrials.gov record NCT07566091, source copy `cardio:ctgov-nct07566091-2026-10-07`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT07566091, source copy `cardio:ctgov-nct07566091-2026-10-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07566091-2026-10-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers
- Acronym: NOVA
- Condition: Coronary Artery Disease
- Intervention (Device): Sirolimus-Ascorbic Acid Eluting Stent
- Intervention (Device): Everolimus-Eluting Stent
- Lead sponsor: Jung-min Ahn
- Lead sponsor class: OTHER
- Collaborator: The CardioVascular Research Foundation (CVRF)
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)

## Provenance

Content hash: c30873fe9bcb44dcad975407a001b4c3825857ce3919c0e5839775229f047fe5
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
